Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Thomas Detry's late birdie assured him of a topSolar sector shrugs off tariff actionExclusive: How a Nigerian king who Harry hailed as one of his 'new inThe reason WHY Beyonce's hit Cowboy Carter album wasn't nominated at the 2024 ACM AwardsBella Hadid displays her jawBradley Cooper branded 'desperate' after studio submits his TWOKylie Jenner sweetly tears up while enjoying fun motherStock market today: World stocks advance after Wall Street closes out another winning weekThe Islamic State claims attack in Afghanistan that killed 3 Spanish citizens and 3 AfghansThe Paralympics open in 100 days. Paris organizers are launching a campaign to boost ticket sales